Everest Medicines (HKSE:01952) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01952 Everest Medicines Ltd HKSE:01952
41 GF Score
Price HK$27.60
GF Value HK$295.50
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HKSE:01952 vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Everest Medicines's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Short Percentage of Float falls into.


HKSE:01952
41GF Score
Everest Medicines Ltd HKSE:01952
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Everest Medicines (HKSE:01952) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of HK$27.60 is trading 90.7% below its estimated GF Value™ of HK$295.50. GuruFocus considers Everest Medicines to be Possible Value Trap.

Key valuation signals for HKSE:01952:

  • Short Percentage of Float:
  • GF Value™: HK$295.50 vs. price of HK$27.60 (90.7% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 6HN:Germany
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
41GF Score

Get the complete analysis for HKSE:01952

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.60
Price
HK$295.50
GF Value